Johnson Fistel Investigates Nutex Health Following Short Report and Delayed SEC Filing

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Nutex Health Inc. regarding possible violations of federal securities laws, particularly related to alleged misrepresentations and omissions by the company and its executives [1] Group 1: Allegations and Concerns - Blue Orca Capital published a report alleging that Nutex Health's recent 20-fold share price surge was artificially driven by a third-party vendor, HaloMD, which facilitated inflated billing awards [3] - The report claims that HaloMD is linked to a fraudulent scheme that siphoned millions from insurers, raising doubts about the legitimacy of Nutex's reported revenue increases [3] - Although Nutex has not been named in any lawsuits, the report warns that insurers may pursue reimbursement or legal action against the company, potentially leading to a collapse in financial performance [3] Group 2: Stock Performance and Financial Reporting - On August 14, 2025, Nutex shares fell approximately 18% after the company announced a delay in filing its quarterly financial statements for the period ending June 30, 2025, due to incomplete accounting adjustments [4]